Skip to content
GERICLINICS

Flashcards · Module 13

🩸 Blood & Cancer (Geriatric Hematology & Oncology)

4 of 4 cards published · read by the site’s author on 17 November 2026

Unexplained Anemia of the Elderly (UAE): Is anemia ever "just old age"?

Needs clinical review

The Golden Rule:

Anemia is not just 'old age': it is a key indicator of underlying conditions, so look for a cause.

What is UAE?

In about one third of older adults with anemia no cause is found: this is Unexplained Anemia of the Elderly (UAE). A third have nutrient deficiency and a third chronic inflammation or kidney disease.

What Drives It? Inflammaging!

  1. 🧪 Chronic low-grade inflammation ("inflammaging")

  2. 🔒 Inflammation and iron: in older people, higher inflammatory markers go with anemia and low iron, but one large study found no rise in hepcidin.

  3. 🫘 Blunted Erythropoietin (EPO): Aging kidneys produce less EPO in response to hypoxia.

  4. 🧱 Marrow disorders: bone marrow failure syndromes are among the causes.

Clinical Impact:

Even mild anemia may substantially affect physical and cognitive capacity and quality of life.

One-Liner: Anemia in older adults is a clue to disease, not normal aging; when it stays unexplained, inflammaging and reduced kidney EPO production are thought to contribute.
Sources checked (3) · 15 November 2026

CHIP (Clonal Hematopoiesis of Indeterminate Potential): The silent plaque inflamer

Needs clinical review

What is CHIP?

Blood stem cells in bone marrow acquire leukemia-associated somatic mutations (most commonly DNMT3A, TET2, ASXL1, JAK2). These mutated stem cells clone themselves so that ≥2% of peripheral blood cells carry the mutation—without any leukemia, lymphoma, or abnormal blood counts.

How Common Is It?

  • Age <40: rare

  • Age 70–79: about 10% (9.5%)

  • Age 80–89: about 12%; 90 and over: about 18%

The Big Surprise (The Board Question!):

You'd think CHIP's main danger is leukemia: it does raise blood cancer risk (hazard ratio 11.1), but it also raises coronary heart disease (2.0) and ischemic stroke (2.6), and all-cause mortality (1.4).

Why CHIP Destroys Arteries:

  • In mice, Tet2-deficient macrophages switch on inflammatory chemokine and cytokine genes.

  • In mice, this accelerated atherosclerosis.

  • In people, CHIP was associated with nearly double the risk of coronary heart disease.

  • Ischemic stroke risk was also higher (hazard ratio 2.6).

One-Liner: CHIP is age-related clonal expansion of blood stem cells with mutations such as DNMT3A and TET2; it nearly doubles the risk of coronary heart disease.
Sources checked (2) · 15 November 2026

Myelodysplastic Syndromes (MDS): Bone marrow failure in older adults

Needs clinical review

The Disease in Plain English:

MDS are myeloid disorders with low blood counts (cytopenias), dysplastic cells in the bone marrow, and a risk of turning into acute myeloid leukemia.

Presentation:

An older adult (median age about 68 in one large series) presents with progressive fatigue, recurrent infections, or easy bruising. Lab: unexplained anemia or bi/pancytopenia.

How We Stratify Risk:

We use the IPSS-R (Revised International Prognostic Scoring System):

  • Marrow blast percentage

  • Cytogenetics (5 risk groups, from very good to very poor)

  • Depth of cytopenias (Hb, platelets, ANC)

Treatment Strategy:

MDS Risk GroupGoalTreatment
Lower-Risk MDSRelieve symptoms & stop transfusions• RBC transfusions + iron chelation
• Erythropoietin (ESA) if serum EPO ≤500 mU/mL
• Lenalidomide (lower-risk MDS with chromosome 5 changes)
Higher-Risk MDSProlong survival & delay AML• Hypomethylating agents (azacitidine, decitabine): azacitidine improved survival over conventional care in the AZA-001 trial
• Allogeneic stem cell transplant for selected patients
One-Liner: MDS are dysplastic myeloid disorders with cytopenias and a risk of AML; treat lower-risk disease for anemia (ESAs, lenalidomide in del5q) and higher-risk disease with hypomethylating agents (azacitidine prolongs survival).
Sources checked (3) · 15 November 2026

Chemotherapy Toxicity in Older Adults: Predicting it with the CARG score

Needs clinical review

Why Standard Oncology Tools Fail:

Older patients have more comorbidities and often a compromised performance status, which makes chemotherapy harder to give safely.
Geriatric assessment adds risk factors such as:

  • Reduced kidney function (creatinine clearance <34 mL/min)

  • Needing help to take medications

  • Multi-agent (combination) chemotherapy

  • A fall in the last 6 months

The danger: Grade 3–5 toxicity (severe, life-threatening or fatal).

The Solution: The CARG Toxicity Score

The Cancer and Aging Research Group (CARG) tool uses 11 validated geriatric variables:

  1. Age ≥72

  2. Cancer type (GI or GU)

  3. Standard planned chemo dose

  4. Multi-agent chemotherapy

  5. Hemoglobin (<11 g/dL in men, <10 in women)

  6. Creatinine Clearance (<34 mL/min)

  7. Hearing impairment

  8. History of falls in last 6 months

  9. Takes medications without assistance (IADL)

  10. Decreased social activities due to health

  11. Ability to walk 1 block

Risk Categories:

  • Low Risk (0–5 pts): ~30% risk of severe toxicity

  • Intermediate (6–9 pts): ~52% risk

  • High Risk (10–19 pts): ~83% risk of severe, life-threatening or fatal toxicity

One-Liner: In older adults, the 11-item CARG score (geriatric assessment plus lab, tumor and treatment factors) predicts Grade 3–5 chemotherapy toxicity: about 30%, 52% and 83% at low, intermediate and high risk.
Sources checked (2) · 15 November 2026